

Shanna Babalonis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3089663/publications.pdf>

Version: 2024-02-01

25
papers

931
citations

567281

15
h-index

580821

25
g-index

25
all docs

25
docs citations

25
times ranked

1022
citing authors

#	ARTICLE	IF	CITATIONS
1	Cannabidiol (CBD) product contamination: Quantitative analysis of Δ^9 -tetrahydrocannabinol (Δ^9 -THC) concentrations found in commercially available CBD products. <i>Drug and Alcohol Dependence</i> , 2022, 237, 109522.	3.2	15
2	Cannabidiol: pharmacology and therapeutic targets. <i>Psychopharmacology</i> , 2021, 238, 9-28.	3.1	129
3	Acute administration of oxycodone, alcohol, and their combination on simulated driving—preliminary outcomes in healthy adults. <i>Psychopharmacology</i> , 2021, 238, 539-549.	3.1	4
4	Relative potency of intravenous oxymorphone compared to other μ opioid agonists in humans—pilot study outcomes. <i>Psychopharmacology</i> , 2021, 238, 2503-2514.	3.1	4
5	Recent Increase in Methamphetamine Use in a Cohort of Rural People Who Use Drugs: Further Evidence for the Emergence of Twin Epidemics. <i>Frontiers in Psychiatry</i> , 2021, 12, 805002.	2.6	8
6	Δ^9 -THC: Legal Status, Widespread Availability, and Safety Concerns. <i>Cannabis and Cannabinoid Research</i> , 2021, 6, 362-365.	2.9	22
7	Therapeutic potential of opioid/cannabinoid combinations in humans: Review of the evidence. <i>European Neuropsychopharmacology</i> , 2020, 36, 206-216.	0.7	19
8	Cannabinoid modulation of opioid analgesia and subjective drug effects in healthy humans. <i>Psychopharmacology</i> , 2019, 236, 3341-3352.	3.1	21
9	Tobacco use during cannabis cessation: Use patterns and impact on abstinence in a National Drug Abuse Treatment Clinical Trials Network study. <i>Drug and Alcohol Dependence</i> , 2018, 192, 59-66.	3.2	21
10	A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults. <i>Drug and Alcohol Dependence</i> , 2017, 177, 249-257.	3.2	109
11	Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers. <i>Drug and Alcohol Dependence</i> , 2017, 172, 9-13.	3.2	106
12	The Abuse Potential of Prescription Opioids in Humans—Closing in on the First Century of Research. <i>Current Topics in Behavioral Neurosciences</i> , 2016, 34, 33-58.	1.7	10
13	A Pharmacokinetic Study Examining Acetazolamide as a Novel Adherence Marker for Clinical Trials. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 324-332.	1.4	19
14	Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers. <i>Drug and Alcohol Dependence</i> , 2016, 162, 190-198.	3.2	10
15	Opioid withdrawal suppression efficacy of oral dronabinol in opioid dependent humans. <i>Drug and Alcohol Dependence</i> , 2016, 164, 143-150.	3.2	45
16	Pharmacodynamic effects of oral oxymorphone: abuse liability, analgesic profile and direct physiologic effects in humans. <i>Addiction Biology</i> , 2016, 21, 146-158.	2.6	15
17	Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis. <i>Neuropsychopharmacology</i> , 2016, 41, 1974-1982.	5.4	160
18	Quinine as a potential tracer for medication adherence: A pharmacokinetic and pharmacodynamic assessment of quinine alone and in combination with oxycodone in humans. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 1332-1343.	2.0	9

#	ARTICLE	IF	CITATIONS
19	Safety of oral dronabinol during opioid withdrawal in humans. <i>Drug and Alcohol Dependence</i> , 2015, 157, 179-183.	3.2	35
20	Efficacy of extended-release tramadol for treatment of prescription opioid withdrawal: A two-phase randomized controlled trial. <i>Drug and Alcohol Dependence</i> , 2013, 133, 188-197.	3.2	27
21	Abuse liability and reinforcing efficacy of oral tramadol in humans. <i>Drug and Alcohol Dependence</i> , 2013, 129, 116-124.	3.2	110
22	Progesterone effects on the discriminative stimulus, subjective and performance effects of triazolam in healthy, premenopausal women. <i>Behavioural Pharmacology</i> , 2011, 22, 441-449.	1.7	1
23	Physiological doses of progesterone potentiate the effects of triazolam in healthy, premenopausal women. <i>Psychopharmacology</i> , 2011, 215, 429-439.	3.1	10
24	Modulation of the discriminative stimulus effects of triazolam across the menstrual cycle phase in healthy pre-menopausal women. <i>Drug and Alcohol Dependence</i> , 2008, 94, 276-280.	3.2	6
25	Evaluation of estradiol administration on the discriminative-stimulus and subject-rated effects of d-amphetamine in healthy pre-menopausal women. <i>Pharmacology Biochemistry and Behavior</i> , 2007, 87, 258-266.	2.9	16